FDA issues may deter drugmakers from engaging in social media, but that's no excuse to ignore what audiences are saying on these platforms

Community Catalyst has declared war on prescription co-pay cards and coupons, calling the sales tools nothing more than kickbacks and bribes.

Why the Susan G. Komen for the Cure Foundation's previously unassailable brand in healthcare fundraising may have sustained some permanent damage.

News of WebMD's planned sale—since aborted—surprised many observers.

Everyone in biopharma knows that manufacturers are spending more to develop drugs that earn less than they did ten years ago, but a new study has put some eye-popping numbers on the industry's dwindling returns.

A little over half of US girls ages 13 to 17 have not gotten even one dose of the HPV vaccine

After Facebook's decision on August 15 to enforce open walls on the site's pharma pages, companies had two options: close down their pages altogether, or let the public openly comment on their products.

Oral anticoagulant Eliquis (apixaban) has demonstrated superior efficacy and bleeding profile to standard warfarin therapy. Barring any bombshells, that should be enough for this agent, being developed by Pfizer and Bristol-Myers Squibb, to get US approval and form a compelling sales narrative in the warfarin-alternative market, analysts say.

The FDA is moving cautiously on a call by the Institute of Medicine (IOM) to scrap the approvals process for many medical devices.

FDA issued draft guidance on mobile medical apps, focusing narrowly on those programs that augment regulated medical devices or turn mobile devices into medical devices.